|1.||Vuorinen, Tytti: 1 article (05/2002)|
|2.||Hyypiä, Timo: 1 article (05/2002)|
|3.||Saraste, Antti: 1 article (05/2002)|
|4.||Harvala, Heli: 1 article (05/2002)|
|5.||Ilbäck, Nils-G: 1 article (05/2002)|
|6.||Fohlman, Jan: 1 article (05/2002)|
|7.||Kytö, Ville: 1 article (05/2002)|
02/01/1992 - "The therapeutic efficacy of an experimental antiviral agent, WIN 54954, was evaluated in murine myocardial infection with coxsackievirus A9 (CVA9). "
02/01/1993 - "The efficacy of oral WIN 54954 for the prevention of rhinovirus infection and illness was tested in two randomized, double-blinded, placebo-controlled volunteer challenge studies. "
02/01/1993 - "These results suggest that the lack of efficacy of WIN 54954 against rhinovirus may be related to an inability to deliver sufficient drug to the site of viral infection."
02/01/1993 - "Efficacy of oral WIN 54954 for prophylaxis of experimental rhinovirus infection."
01/01/1998 - "WIN 54954 (0.025-1 microg/ml) application was started 7 days after infection of the cultures. "
05/01/2002 - "Cardiomyocyte apoptosis after antiviral WIN 54954 treatment in murine coxsackievirus B3 myocarditis."
01/01/1993 - "Therapy of coxsackie virus B3-induced myocarditis with WIN 54954 in different formulations."
02/01/1992 - "Treatment of Coxsackievirus A9 myocarditis in mice with WIN 54954."
01/01/1993 - "The antiviral efficacy of WIN 54954 was demonstrated in vivo in a Coxsackie B 3 virus (Woodruff strain) induced myocarditis mouse model. "
05/01/2002 - "WIN 54954, a compound that inhibits early events of picornavirus infection, is known to dramatically reduce mortality in murine CVB3 myocarditis without abrogating systemic or myocardial inflammation. "
01/01/1998 - "In situ hybridization demonstrated that at 0.1 microg/ml WIN 54954 reduced the number of infected cells from 0.99 to 0.18%, although a complete eradication of CVB2-infected cells was not achieved at concentrations as high as 1 microg/ml. In conclusion, the results indicate that low concentrations of WIN 54954 are effective in treating persistent enterovirus infections of myocardial fibroblasts, although a complete eradication of the infection is not achieved with WIN 54954 as a single antiviral agent."
08/01/1993 - "The therapeutic efficacy of an experimental antiviral agent, WIN 54954, was evaluated in a mouse model in which infection by coxsackievirus B4 (CVB4) strain E2 was followed by diabetes mellitus. "
08/01/1993 - "Thus, WIN 54954 effectively reduces virus replication and islet histologic changes acutely and decreases, at 7 weeks, both the metabolic alteration associated with diabetes mellitus and the incidence of detectable viral RNA in the pancreas."
|5.||Body Weight (Weight, Body)
08/01/1993 - "WIN 54954 was administered orally via gavage tube in a dose of either 5 or 50 mg/kg of body weight per day. "
02/01/1992 - "WIN 54954, a broad-spectrum antipicornavirus agent, was administered orally in a dose of 0.25, 2.5, 25, 50, 100, or 200 mg/kg of body weight per day on days 1 to 3 after virus inoculation. "
|1.||L 644711 (B-3(+))
|3.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|6.||Interferon-gamma (Interferon, gamma)